A gene therapy trial for transfusion-dependent thalassaemia, an inherited blood disorder, gave positive...
- AACR 2018: SLFN11 predicts response to PARP inhibition in small cell lung cancer
- TaiwanJ’s JKB-121 falls victim to unexpected placebo response in NASH patients
- ILC 2018: NGM’s intravenous NASH therapy shows rapid reduction in liver fat content and fibrosis
- CD40 agonist developments could support Anti-PD-(L)1 therapy in pancreatic cancer
- ILC 2018: Allergan’s cenicriviroc shows continued fibrosis response in NASH patients in two year extended study
Gene therapy for beta-thalassaemia could eliminate need for transfusions
A gene therapy trial for transfusion-dependent thalassaemia, an inherited blood disorder, gave positive results in an interim analysis, with the majority of patients being transfusion-free following treatment.
Low-cost anti-hookworm treatment found to be effective
A study co-authored by Yale researchers and non-profit company InnovationsCZ has reported the efficacy of a low-cost deworming drug in farm workers infected with hookworms.
AACR 2018: revisiting murine models to develop drug combos for KRAS-driven cancers
Treatment of KRAS-driven cancers is among one of the highest unmet needs in the oncology space.
AACR 2018: SLFN11 predicts response to PARP inhibition in small cell lung cancer
This year’s AACR meeting provided exciting preliminary data for additional therapeutic biomarkers in SCLC
TaiwanJ’s JKB-121 falls victim to unexpected placebo response in NASH patients
The future of TaiwanJ Pharmaceuticals’ JKB-121 as a NASH treatment is in jeopardy after it failed to demonstrate efficacy in a Phase II placebo-controlled trial, presented at the 2018 International Liver Congress (ILC) in Paris, France.
ILC 2018: NGM’s intravenous NASH therapy shows rapid reduction in liver fat content and fibrosis
Phase II efficacy data for NGM Biopharmaceuticals’ developmental non-alcoholic steatohepatitis (NASH) drug, NGM282, was presented at the 2018 International Liver Congress (ILC) in Paris, France.
Potential drug target for anti-obesity treatment discovered
Researchers have determined the molecular structure of the neuropeptide Y1 receptor (Y1R), a protein of central importance in food intake, which paves the way for new treatments for diseases such as obesity, type 2 diabetes and metabolic syndrome.
AstraZeneca announces OS data from breast cancer treatment Lynparza
AstraZeneca and Merck have announced overall survival (OS) data from Phase III trial OlympiAD examining Lynparza (olaparib) as a treatment for metastatic breast cancer.
CD40 agonist developments could support Anti-PD-(L)1 therapy in pancreatic cancer
A major theme of this year’s AACR meeting examines the approaches that aim to further improve the anti-tumour efficacy of anti-PD-1 and –PD-L1 checkpoint inhibitors (CPIs) in the clinic.
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.